Stoke Therapeutics, Inc. (STOK)
| Market Cap | 2.04B +92.9% |
| Revenue (ttm) | 27.59M -86.2% |
| Net Income | -207.90M |
| EPS | -3.33 |
| Shares Out | 64.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 754,092 |
| Open | 32.20 |
| Previous Close | 32.59 |
| Day's Range | 31.49 - 32.55 |
| 52-Week Range | 18.80 - 40.22 |
| Beta | 1.23 |
| Analysts | Strong Buy |
| Price Target | 46.46 (+46.93%) |
| Earnings Date | Aug 3, 2026 |
About STOK
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome i... [Read more]
Financial Performance
In 2025, Stoke Therapeutics's revenue was $184.42 million, an increase of 404.50% compared to the previous year's $36.56 million. Losses were -$6.89 million, -92.26% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for STOK stock is "Strong Buy." The 12-month stock price target is $46.46, which is an increase of 46.93% from the latest price.
News
Stoke Therapeutics reinstated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of Stoke Therapeutics (STOK) with an Overweight rating and $40 price target The firm sees a high probability of success for zorevunersen’s Phase III…
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong retention, zero dropouts, and promising long-term efficacy in both seizure reduction and cognitive gains. Rolling NDA submission is planned for 2027, with long-term data expected to drive value and payer support.
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics price target lowered to $58 from $60 at Canaccord
Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Stoke Therapeutics (STOK) to $58 from $60 and keeps a Buy rating on the shares. The firm updated their model…
Stoke Therapeutics Earnings Call Transcript: Q2 2026
Phase III EMPEROR study for zorevunersen in Dravet syndrome completed enrollment with strong patient retention and no discontinuations. Financial position remains robust with $420 million in cash, supporting operations through a potential U.S. launch in early 2028. NDA submission is planned for 2027, with commercial and pipeline progress ongoing.
Stoke Therapeutics Earnings release: Q2 2026
Stoke Therapeutics released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Stoke Therapeutics Quarterly report: Q2 2026
Stoke Therapeutics has published its Q2 2026 quarterly earnings report on August 3, 2026.
Stoke Therapeutics Slides: Q2 2026
Stoke Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Stoke Therapeutics reports Q2 EPS (93c), consensus (78c)
Reports Q2 revenue $9.325M, consensus $5.09M. “We have made significant progress across our business this year, including the rapid enrollment of 162 patients into the Phase 3 EMPEROR study and…
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics appoints McCauley as Chief Scientific Officer
Stoke Therapeutics (STOK) announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. McCauley most recently served as the President and Chief Executive Officer of Neptune Bio ...
Stoke Therapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Kevin Strang initiated coverage of Stoke Therapeutics (STOK) with a Buy rating and $44 price target The firm believes the company’s lead asset, zorevunersen, could be the…
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR study
Stoke Therapeutics (STOK) announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolling New Drug Application, NDA, submission...
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Leadership emphasized advocacy and rapid organizational build-out, with zorevunersen showing durable seizure reduction and cognitive gains in Dravet syndrome. Phase III is nearing full enrollment, with a rolling NDA submission planned for 2027 and a concentrated U.S. launch strategy targeting 6,000 patients. Financials are strong, and Biogen partnership supports global expansion.
Stoke Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The lead therapy for Dravet syndrome shows durable seizure reduction and cognitive gains over four years, with phase III data expected mid-2027 and a rolling NDA submission planned. Market research supports premium pricing, and the company is well-financed through launch.
Stoke Therapeutics Transcript: AGM 2026
The meeting covered director elections, ratification of the accounting firm, and executive compensation approval. A quorum was established, all proposals passed, and a Q&A session addressed stakeholder questions and risks.
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics reports Q1 EPS (79c), consensus (84c)
Reports Q1 revenue $6.23M, consensus $5.88M.
Stoke Therapeutics Earnings Call Transcript: Q1 2026
Four-year OLE data show durable seizure reduction and cognitive gains with zorevunersen, supporting its disease-modifying potential. EMPEROR phase III enrollment is nearly complete, with a strong financial runway into 2028 and robust commercial planning underway.
Stoke Therapeutics Earnings release: Q1 2026
Stoke Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Stoke Therapeutics Slides: Q1 2026
Stoke Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Stoke Therapeutics Quarterly report: Q1 2026
Stoke Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.